Securing Today's Biomanufacturing Supply Chain Using Transformative Supply

By Sofie Stille, GM BioProcess Resins & Technologies and Elles Steensma, Program leader, Cytiva

Today, biologics represent a $250 billion industry, which is two times what it was worth only 10 years ago.¹ It is estimated that in just four to five years biologics will make up around 50 percent of the 100 top-selling drugs, corresponding to nearly 30 percent of the total market.² Though monoclonal antibodies are expected to continue dominating the market, a more diversified pipeline that includes, for example, DNA and RNA molecules and cell and gene therapies is anticipated as the growth continues.

Responding to the rapidly changing requirements of these novel therapies means tackling some of the biggest challenges that have the potential to hinder this evolution. One such area is sustainability and security in the biopharmaceutical supply chain.